Due Diligence (4)

Challenge: Our client, a research incubator, accelerator and seed funder within the biotechnology and life science arena, runs two programs in which companies/projects are selected through open...

Challenge: A clinical stage company developed two series of small molecules to treat Alzheimer Disease (AD) and other central nervous system (CNS) indications. Their lead asset aims for symptomatic...

Challenge: A pharma company developing a first-in-class therapeutic to treat rare paediatric neurodegenerative disorders was nearing NDA approval in multiple indications and was ready to initiate...

Challenge: A midsize speciality pharmaceuticals company has retained Alacrita to conduct a series of due diligence assessments to support its business development function. The client focuses on a...

Challenge: Our client, a global pharmaceutical company, was facing a short deadline to making an offer for a late stage gene therapy asset and was under considerable competitive deal pressure. This...

Challenge: A European investor asked Alacrita to conduct a due diligence exercise on a company that had developed a novel single chain antibody platform with its lead product in ADC format ahead of a...

Due Diligence Challenge: An investor was considering re-investing into a development-stage microbiome company that had experienced certain issues that delayed timelines and changed the risk profile....

Alacrita frequently works on behalf of investors to conduct due diligence on prospective transactions. The two case studies below offer a snapshot of the typical expertise we provide in this area. To...

Challenge: A private equity fund approaching an investment in a Phase III asset required an expert evaluation of the likelihood of success in the Phase III trial. The molecule, targeted at two CNS...

Challenge: A private equity investor was considering a transaction in a company supplying therapeutic proteins derived from biological sources for the treatment of numerous diseases in the...

Challenge: A well-capitalized Swiss pharma company needed a clinical and commercial reality check for a new imaging technology being developed that was under consideration for acquisition.

Challenge: A VC investor wished to make an investment in a California-based preclinical biotechnology company with a discovery platform and novel T cell therapies for cancer and other diseases....